Clinical Trials Logo

Clinical Trial Summary

Twenty-Eight (28) subjects (12 for cohort 1 and 16 for cohort 2 ) will be included in the study. Subjects in each cohort will be injected with a different dose of RZL-012. The total of 28 subjects will be enrolled in 2 clinical sites.


Clinical Trial Description

This is a single blinded, randomized, placebo-controlled, 2-cohort clinical study in healthy volunteers. Cohort 1 will be comprised of 8 active (RZL-012) and 4 placebo subjects. Cohort 2 will be comprised of 16 subjects wuth at least 4 placebo subjects. All subjects will receive a single dose of RZL-012 or vehicle into the submental area, after which they will be monitored for safety and efficacy during 84 days of follow-up.

Subjects will be blinded to study treatment while physicians will not be blinded.

The study will be composed of 2 treatment cohorts, 12 in cohort 1 and 16 in cohort 2.

The study will be conducted in 2 clinical sites. Per each study cohort, subjects will be randomized to receive active or placebo treatment according to a randomization program that will be prepared prior to study initiation. Each clinical site will have at least one active and one placebo treatment subject per each study cohorts. In case of slow enrollment in one of the sites, other sites may complete the enrollment of subjects in each cohort.

Cohort 1 (N=12) - Each subject will be dosed with up to 120 mg RZL-012 (depending on submental fat area) or vehicle.

Cohort 2 (N=16) - Each subject will be dosed with up to 240 mg RZL-012 (depending on submental fat area) or vehicle.

Treatment of cohort 2 will start following cohort 1 day 28 data. An independent Data Safety Monitoring Board (DSMB) will review safety and tolerability data for cohort 1 subjects, 28 days after injection, and decide whether it is safe to increase the dose for the next study cohort. The decision to proceed to the cohort 2 will be made within 30 days (28 days + 2 days) after injection of the last dosed subject in cohort 1.

The DSMB will be comprised of two independent MDs with expertise in the aesthetic area and in conduction of clinical trials.

In case of serious safety concerns (e.g. prolonged severe swelling or severe pain following injection) among cohort 1 subjects receiving the 120mg dose, sponsor and DSMB may decide to reduce or stay with the 120mg/subject dose level for cohort 2 subjects. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04086823
Study type Interventional
Source Raziel Therapeutics Ltd.
Contact
Status Completed
Phase Phase 2
Start date February 25, 2020
Completion date September 16, 2020

See also
  Status Clinical Trial Phase
Completed NCT04144049 - A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat Phase 2
Active, not recruiting NCT04258761 - A Safety and Tolerability Study of 10XB-101 Injections in Adult Subjects With Extra Fat Under the Chin ("Double Chin") Phase 2
Recruiting NCT03946592 - Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat Phase 3
Recruiting NCT04867434 - Efficacy and Safety of RZL-012 on Submental Fat Reduction Phase 2
Completed NCT02159729 - Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101 Phase 2
Completed NCT03005717 - Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat Phase 2
Completed NCT02163902 - Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101 Phase 3